Jyong Biotech (NASDAQ:MENS) Reaches New 52-Week Low - Here's Why

Jyong Biotech Ltd. (NASDAQ:MENS - Get Free Report)'s share price hit a new 52-week low during mid-day trading on Wednesday . The company traded as low as $2.81 and last traded at $2.92, with a volume of 3192141 shares changing hands. The stock had previously closed at $15.40.Get Jyong Biotech alerts:Analyst Upgrades and DowngradesSeparately, Weiss Ratings reiterated a "sell (e+)" rating on shares of Jyong Biotech in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Jyong Biotech has a consensus rating of "Sell".Read Our Latest Research Report on MENSJyong Biotech Trading Down 81.0%The company has a fifty day moving average of $39.02. Institutional Investors Weigh In On Jyong BiotechAn institutional investor recently bought a new position in Jyong Biotech stock. BNP Paribas Financial Markets purchased a new position in shares of Jyong Biotech Ltd. (NASDAQ:MENS - Free Report) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 1,698 shares of the company's stock, valued at approximately $67,000. About Jyong Biotech (Get Free Report)OUR MISSION We endeavor to develop and supply first-class innovative drugs to meet our customers' health needs. We seek to be a valuable business organization that is held in high esteem by the public. We are a science-driven biotechnology company based in Taiwan and are committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU, and Asia.Read MoreFive stocks we like better than Jyong BiotechHow to Know if a Stock Pays Dividends and When They Are Paid OutPost 35% Surge, Analysts Eye More Upside in Copper Giant FreeportHow to Invest in Insurance Companies: A Guide Why a SpaceX IPO Could Be a Major Catalyst for GOOGL Stock3 Small Caps With Big Return PotentialCan Upwork Maintain Its Comeback? Reasons to Be Bullish and BearishThis instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in Jyong Biotech Right Now?Before you consider Jyong Biotech, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Jyong Biotech wasn't on the list.While Jyong Biotech currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here